Trial Profile

A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects With Advanced Melanoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBI 363 (Primary)
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use
Sponsors Innovent Biologics

Most Recent Events

02 Mar 2025 According to Innovent Biologics media release, updated data from this trial will be shared at international conferences in 2025.
02 Mar 2025 Results presentd in the Innovent Biologics Media Release.
02 Mar 2025 According to Innovent Biologics media release, data from this trial were presented at SITC 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com